All In Biotech

Drug Trial Radar · NCT05958407

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy

A Phase 3b, Interventional, Adaptive, Clinical Trial to Evaluate the Efficacy and Safety of Tralokinumab 300 mg Every Second Week Monotherapy Compared With Placebo in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 235 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

235

Actual

Start

Aug 28, 2023

Primary completion

May 5, 2025

Study completion Sep 22, 2025

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Jul 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test if treatment with tralokinumab is safe and efficacious in treating moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks for each participant. There will be up to 15 visits for each participant, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to 4 weeks. For the first 16 weeks after screening, trial participants will receive either tralokinumab or dummy injections every two weeks. After the first 16 weeks, all trial participants will receive tralokinumab injections every two weeks for 16 weeks. The last part of the trial is a period of 4 weeks after the end of treatment period, where trial participants will not receive tralokinumab but are monitored for safety.

Conditions

  • Atopic Dermatitis
  • Atopic Hand Eczema

Interventions

  • TralokinumabDrug

    After a loading dose of 600 mg under the skin (s.c.) at baseline, trial participants are administered a dose of 300 mg every two weeks for 32 weeks

  • PlaceboDrug

    After a loading dose under the skin (s.c.) at baseline, trial participants are administered a placebo dose every two weeks for 16 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear)Time frame: At Week 16

Locations

69 sites in 10 countries. Site status is shown where the registry gives one.

  • LEO Pharma Investigational Site

    Birmingham, Alabama

  • LEO Pharma Investigational Site

    Fort Smith, Arkansas

  • LEO Pharma Investigational Site

    Fountain Valley, California

  • LEO Pharma Investigational Site

    Los Angeles, California

  • LEO Pharma Investigational Site

    Sacramento, California

  • LEO Pharma Investigational Site

    Farmington, Connecticut

  • LEO Pharma Investigational Site

    Hialeah, Florida

  • LEO Pharma Investigational Site

    Plainfield, Indiana

  • LEO Pharma Investigational Site

    Louisville, Kentucky

  • LEO Pharma Investigational Site

    New Orleans, Louisiana

  • LEO Pharma Investigational Site

    Bangor, Maine

  • LEO Pharma Investigational Site

    Caledonia, Michigan

  • LEO Pharma Investigational Site

    Detroit, Michigan

  • LEO Pharma Investigational Site

    Portsmouth, New Hampshire

  • LEO Pharma Investigational Site

    Cortland, New York

  • LEO Pharma Investigational Site

    New York, New York

  • LEO Pharma Investigational Site

    Portland, Oregon

  • LEO Pharma Investigational Site

    Portland, Oregon

  • LEO Pharma Investigational Site

    Nashville, Tennessee

  • LEO Pharma Investigational Site

    Dallas, Texas

  • LEO Pharma Investigational Site

    Frisco, Texas

  • LEO Pharma Investigational Site

    San Antonio, Texas

  • LEO Pharma Investigational Site

    Webster, Texas

  • LEO Pharma Investigational Site

    Brussels, Belgium

  • LEO Pharma Investigational Site

    Edegem, Belgium

  • LEO Pharma Investigational site

    Ghent, Belgium

  • LEO Pharma Investigational Site

    Québec, Canada

  • LEO Pharma Investigational Site

    Québec, Canada

  • LEO Pharma Investigational Site

    Calgary, Alberta, Canada

  • LEO Pharma Investigational Site

    Edmonton, Alberta, Canada

  • LEO Pharma Investigational Site

    Edmonton, Alberta, Canada

  • LEO Pharma Investigational Site

    Red Deer, Alberta, Canada

  • LEO Pharma Investigational Site

    Surrey, British Columbia, Canada

  • LEO Pharma Investigational Site

    Fredericton, New Brunswick, Canada

  • LEO Pharma Investigational Site

    Hamilton, Ontario, Canada

  • LEO Pharma Investigational Site

    Richmond Hill, Ontario, Canada

  • LEO Pharma Investigational Site

    Toronto, Ontario, Canada

  • LEO Pharma Investigational Site

    Windsor, Ontario, Canada

  • LEO Pharma Investigational Site

    Saint-Jérôme, Quebec, Canada

  • LEO Pharma Investigational Site

    Nantes, France

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.